PREVYMIS (letermovir), antiviral

High clinical benefit and minor clinical improvement in the prevention of CMV reactivation and CMV disease after allogeneic haematopoietic stem cell transplantation

• PREVYMIS has MA for the prevention of cytomegalovirus (CMV) reactivation and CMV disease in adult CMV-seropositive allogeneic haematopoietic stem cell transplantation (HSCT) recipients [R+].

• It has demonstrated its efficacy, particularly in terms of the reduction of pre-emptive treatment initiation, with no blood toxicity.

• Its clinical impact on mortality, the incidence of CMV disease or the onset of graft-versus-host disease (GvHD) has yet to be demonstrated.